title: Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine.
abstract: In this randomized, double-blind, placebo study, the respiratory effects of a single dose of sublingual buprenorphine (0.4 mg) were examined and compared with those induced by one dose of intramuscular morphine (10 mg) in a population of women, aged 25-65 years, admitted at the Hospital for Elective Surgery because of uterine fibromyomatosis. Some indices of control of breathing (P0.1, VT/TI, VE, VA, TI, TE, TI/TTot, RR), gas exchange parameters (D[A-a]O2, VD/VT, PAO2) and blood gases (PaO2, PaCO2) were measured in basal condition and at 30, 60, 90, 180 and 360 min after the administration of the drugs. No significant changes of the respiratory function were observed in patients who have received sublingual buprenorphine. In the morphine-group, however, mild PaO2 decrease and PaCO2 increase were found at 60 and 90 min (p less than 0.05), without any reduction of the respiratory drive activity, as shown by P0.1, VT/TI and VE. The significant FRC reduction, observed in the morphine-group (p less than 0.05), could have induced both TE shortening and RR increase with larger dead space ventilation and consequent fall of VA (p less than 0.05). These results suggest that the administration of one dose of sublingual buprenorphine (0.4 mg) does not cause any detrimental respiratory effect; on the other hand, an appreciable, although clinically trivial, worsening of the respiratory function results from intramuscular morphine (10 mg), in the absence of any obvious respiratory depression.
authors.affiliation: Istituto di Semeiotica e Metodologia Medica, Università di Ancona, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Tantucci
authors.forename: F
authors.initials: F
authors.lastname: Paoletti
authors.forename: B
authors.initials: B
authors.lastname: Bruni
authors.forename: M L
authors.initials: ML
authors.lastname: Dottorini
authors.forename: F
authors.initials: F
authors.lastname: Peccini
authors.forename: A
authors.initials: A
authors.lastname: Boanelli
authors.forename: R
authors.initials: R
authors.lastname: Belfiori
authors.forename: V
authors.initials: V
authors.lastname: Pasqualucci
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D005652:Functional Residual Capacity / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000601:surgery; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012119:Respiration / Q000187:drug effects*; D013990:Tidal Volume / Q000187:drug effects; D013997:Time Factors; D014594:Uterine Neoplasms / Q000601:surgery
chemical_list: D002047:Buprenorphine; D009020:Morphine